Oct 2, 2017
Crestovo Doses Recurrent C. diff. Infection Patients In PRISM 3 - A Phase 2 Clinical Trial Testing CP-101 Microbiota
Crestovo Doses Recurrent C. diff. Infection Patients In PRISM 3 – A Phase 2 Clinical Trial Testing CP-101 Microbiota
Crestovo doses recurrent Clostridium difficile infection (C. difficile) patients in PRISM 3, a phase 2 clinical trial testing CP101 (Microbiota).
The company is developing a Full-Spectrum Microbiota that harnesses the human gut microbiome. CP101, a first-in-class, lead microbiome therapy, is an encapsulated, single dose, orally-administered medicine that contains the full complement of…
View On WordPress